Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Our previous study provided some evidence that the
2022-06-02

Our previous study provided some evidence that the pre-treatment of livers with rapamycin induces the expression of HO-1 and Prx-1 (Kist et al., 2012). The present results define the dose-response curve for the induction of HO-1 and Prx-1 expression by rapamycin in normal hepatocytes. While, in the
-
The rationale for developing HDACi as
2022-06-02

The rationale for developing HDACi as anticancer agents was based on their ability to induce the hyperacetylation of histones and nonhistone proteins, resulting in increased differentiation, apoptosis, and Ivacaftor benzenesulfonate arrest of cancer cells 1, 2, 3. HDACi have been used in the treatm
-
Ning et al showed that LPC appeared to increase insulin
2022-06-02

Ning et al. showed that LPC 18:1 appeared to increase insulin release through both GPR119-dependent and -independent mechanisms (Ning et al., 2008). In our study, we have shown that not only GPR119 but also GPR40 and GPR55 participate in LPC-stimulated insulin secretion (Fig. 4, Fig. 5) and target p
-
Consistent with other studies on the metabolic effects of an
2022-06-02

Consistent with other studies on the metabolic effects of an OM3 enriched diet [26,104,105], irrespective of gender, the lowest glucose levels were seen in the Bob-Cat groups fed OM3 diet. Sexual dimorphism was observed in insulin levels. The highest average levels were in the HFD fed [Tg(CAT)±] mal
-
Concanamycin A Molecular modeling studies also revealed insi
2022-06-02

Molecular modeling studies also revealed insignificant differences in ligand-receptor interaction energies between R and S enantiomers of LPCs or their 2-OMe-analogues, suggesting that enantiomers of a particular structure should exert similar GPR119-mediated biological effect. Indeed, when studied
-
fiin Finally we investigated increasing basicity as a way
2022-06-02

Finally, we investigated increasing basicity as a way to improve solubility. We expected that conversion of the ether linkage of to an -methyl group could improve solubility. More than expected, fiin demonstrated significant improvement of values of solubility for the two media, especially for ac
-
Recently a G protein coupled receptor GPR a
2022-06-02

Recently, a G-protein-coupled receptor, GPR109a, was identified as a molecular target for niacin. Following this breakthrough, our group initiated a drug discovery program focused on the development of a high affinity ‘flush-free’ niacin-like agonist. Previously, we reported on the identification of
-
Reports of hyperlocomotion after administration of ALX
2022-06-02

Reports of hyperlocomotion after administration of ALX-5407 [27] coupled with the lack of hyperlocomotion after administration of SSR504734, a non-sarcosine, long-residence time, competitive inhibitor [19], suggested that the GlyT1 inhibitor chemotype may impact OP. Furthermore, a compound with a co
-
Both anxiety like behavior and sucrose preference
2022-06-01

Both anxiety-like behavior and sucrose preference/intake were reduced in GPR40/FFAR1 KO male mice, while social behavior was normal in KO mice. These findings indicate that brain GPR40/FFAR1 is involved in the modulation of anxiety- and depression-like behavior in rodents. Previous studies have demo
-
A number of GCK activators for treating T D
2022-06-01

A number of GCK activators for treating T2D have been developed and tested but not progressed successfully from clinical trials into therapy [45]. Our observations suggest that increased risk of hypoglycemia might be possible, particularly if drugs penetrate into brain. A further possibility is that
-
GLP and glucose dependent insulinotropic peptide GIP are
2022-06-01

GLP-1 and glucose-dependent insulinotropic peptide (GIP) are gut hormones secreted from intestinal L more and K cells, respectively. Together, these hormones account for the vast majority of the incretin effect, the enhanced postprandial insulin secretion observed in healthy adults (Dupre et al., 1
-
The most ubiquitous serine threonine phosphatases
2022-06-01

The most ubiquitous serine/threonine phosphatases, such as PP1, PP2A, and PP2B are known to contribute to the majority of phosphatase activity in the heart [4]. Dysregulation of these and other PPs have been found in numerous CVDs, including heart failure (HF), and may play a critical role in reduce
-
br Presenilins and Wnt catenin signalling Several
2022-06-01

Presenilins and Wnt/β-catenin signalling Several groups have provided substantial data indicating that PS1 acts as a negative modulator of the transcriptional activity of the β-catenin/Tcf-4 complex (Fig. 4) [120], [121], [122]. β-Catenin is a multifunctional protein that was first described as a
-
br Experimental section br Results
2022-06-01

Experimental section Results and discussion Conclusions To summarize, the act of conjugating a ASC ligands to a Ru(II) polypyridyl subunits resulted in a class of excellent DNA binders. A comparison of the DNA binding abilities of the free ASC ligand and the complexes, has revealed that the
-
br The potential of EPA
2022-06-01

The potential of EPA-Ffar4 signaling as a novel intervention for HFpEF Conclusions and future directions Optimization of ω3-PUFA/EPA-therapy based upon titration to achieve therapeutic levels: A pressing clinical challenge is to continue to define the benefit of ω3-PUFA/EPA-therapy. Recent ana
15748 records 429/1050 page Previous Next First page 上5页 426427428429430 下5页 Last page